RANI

Rani is a clinical-stage biotherapeutics company with no approved products and, in its own words, "we have not yet generated any revenue from sales of a commercial product" — the $1.63M of FY2025 revenue is collaboration/grant income, not product sales, and revenue has been erratic ($2.72M→$0→$0→$1.03M→$1.63M across FY2021-25). The entire value rests on the unproven RaniPill oral-delivery platform, which management concedes "we expect will take a number of years" to develop. The lead clinical event is an early-stage Phase 1 trial of RT-114 (a GLP-1/GLP-2 dual agonist for obesity) only initiated in December 2025 — a single shot in a notoriously high-attrition crowded field. This is a binary, unknowable outcome, which squarely fits an 'avoid' rather than a stock that can be valued on fundamentals.

The balance sheet looks superficially clean — $18.6M cash, zero long-term and current debt (both retired to $0.00), equity rebuilt to $33.0M (+1,557% YoY) and liabilities/equity of just 0.52x. But operating losses of -$38.3M and operating cash burn of -$18.7M mean the $18.6M cash on the FY2025 books is roughly one year of runway. Survival depends on capital markets, and the cost of that survival is severe dilution: the October 2025 private placement sold 42.6M shares plus warrants for up to 125M common and 82.4M pre-funded warrants (~$60.3M gross), on top of a share count that already grew +132.3% YoY. Holders of a $0.76 Nasdaq sub-dollar stock face relentless dilution before any product nears approval.